Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp ADR (NQ: AMRN )

0.9160 -0.0040 (-0.43%)
Streaming Delayed Price Updated: 12:51 PM EDT, May 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amarin Corp ADR

< Previous 1 2 3 4 5 6 Next >
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports First Quarter 2024 Business Update and Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients 
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces Results of Annual General Meeting of Shareholders
- Shareholders Approve Share Repurchase Program of up to $50 Million - 
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
From Amarin Corporation plc
Via GlobeNewswire
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action 
From Amarin Corporation plc
Via GlobeNewswire
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
From Amarin Corporation plc
Via GlobeNewswire
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039 
From Amarin Corporation plc
Via GlobeNewswire
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
From Amarin Corporation plc
Via GlobeNewswire
Amarin Chairman & CEO Issue Letter to Shareholders
From Amarin Corporation plc
Via GlobeNewswire
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Amarin Corporation plc
Via GlobeNewswire
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Third Quarter 2023 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
From Amarin Corporation plc
Via GlobeNewswire
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
-- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting -- 
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Present at the 2023 Cantor Global Healthcare Conference
From Amarin Corporation plc
Via GlobeNewswire
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
From Amarin Corporation plc
Via GlobeNewswire
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
From Amarin Corporation plc
Via GlobeNewswire
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Second Quarter 2023 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing Expertise in the Region 
From Amarin Corporation plc
Via GlobeNewswire
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
From Amarin Corporation plc
Via GlobeNewswire
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
From Amarin Corporation plc
Via GlobeNewswire
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
From Amarin Corporation plc
Via GlobeNewswire
Amarin Appoints Patrick Holt as President and Chief Executive Officer
From Amarin Corporation plc
Via GlobeNewswire
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
From Amarin Corporation plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.